In 2012, the
FDA began an initiative to involve patients in the drug development process. They identified 39 potential diseases of which PAH was one. Through their public process, the candidate diseases grew to 90. For each of the selected 20 disease areas during the five year course of this effort, the FDA will conduct a public meeting to discusss the disease and its impact on patients' daily lives, the types of treatment benefit that matter most to patients, and patients' perpectives on the adequacy of available therapies.
Besides patients, the meetings will include participation of FDA review divisions.
Today, we got the great news that PAH is one of the 20 selected diseases for participation!
After our Washington rep, Dane Christiansen notified us, here's what PHA's Advocacy and Awareness Director, Katie Kroner, wrote in her announcement...
In October, PH patient and PHA Board Member, Colleen Brunetti, represented the PH community before the Food and Drug Administration
(FDA). In her testimony, Colleen argued for the inclusion of PAH in FDA’s new
patient focused drug development initiative.
The goal of this initiative is to engage those living with a
wide variety of diseases in giving input to the FDA about how the drug and
device approval processes can be adapted to better meet patients’ needs. For
example, FDA will seek input on the way they assess risk versus benefit during
the approval process for new drugs and devices.
FDA selected 20 disease communities to work with over the
next three years and the PAH community is one of them! Several diseases
associated with PAH are also among the 20 selected, including sickle cell,
HIV and idiopathic pulmonary fibrosis.
PHA plans to use this opportunity to build a long-term,
collaborative relationship with FDA that will benefit the entire PH community
well beyond the term of the initial project. We look forward to updating you as
we learn more.
So, PHA was successful and, as always, that success emerged from the "power of one" - an individual willing to step forward and unite with other individuals in the fight against PH.
Like Colleen,
you can make a difference, too. PHA's
435 Campaign matches patients and families with your own Member of Congress. Over time - and with PHA's help - you can develop a relationship with your Congressman or Congresswoman. The late Speaker of the House, Tip O'Neill often said "all politics is personal". He was so right...and it's also true that all politics is local. Your House Member or Senators want to hear from you and they will respond. We can only win the battles we must continue to fight if we work together.
We very much need you. If you would like to find out more about how you can help with your Member of Congress through the
435 Campaign (or make a connection with your local media through PHA's
PHAware Campaign), contact Elisabeth Williams at
ElisabethW@PHAssociation.org.
I'll close this blog with Colleen's testimony. She made a difference...and so can you.
Drop Elizabeth an email today!
Colleen's Testimony
Hello, thank you for having me here today. Before I
begin I would like to extend my sincerest thanks to the FDA for undertaking
this tremendously important Patient-focused Drug Development initiative. My name is Colleen Brunetti and I am a pulmonary
hypertension patient, looking to my coming 5-year anniversary of diagnosis.
I was diagnosed at the age of 28. I went from a young mom
and wife, quickly climbing the ladder in a successful career, to suddenly
facing down my own mortality with a disease that I was originally led to
believe might kill me in less than five years. I went from planning a life to
worrying that I might not see my baby boy reach Kindergarten.
Well, that baby boy entered first grade this fall, and I was
there. And I’ve learned a lot.
When you get a diagnosis of pulmonary hypertension, or PH
for short, your life changes. For some patients, it means a sudden stop of
activities once enjoyed, because you quickly find you no longer have the breath
or endurance to sustain them. For other patients, it is finally the answer they
were seeking, after too long of searching for an explanation to their symptoms.
Because PH is
often misdiagnosed, many who finally get a diagnosis are already in advanced
stages, with quality of life severely impacted. Medications can help, but often
with severe side effects. The only cure remains a lung and sometimes also heart
transplant.
Medication can mitigate symptoms of PH and slow disease
progress, and that could be dramatic, or minor, or temporary, depending on the
patient.
I have responded well to therapy, although this was not
always the case. But I am always acutely aware that this improvement could be
temporary. I’m doing great. But PH is still PH. It’s still progressive and the
ultimate treatments are still extreme
The Pulmonary Hypertension Association
has blazed a trail of research, education and support. Patients, doctors,
caregivers, allied health professionals, volunteers… all coming together to put
hope in action, and to spur us forward until we do indeed reach a cure.
Please select “pulmonary arterial hypertension” and “organ
transplantation” as disease areas for the initial 5-year pilot program of the
Patient-focused Drug Development Initiative. PHA and the PH community are
dedicated to working with FDA in a meaningful and constructive way to ensure
this pilot program is a success. It is not only our goal to see that the
patient experience better informs regulatory decision-making for PH, but that
this effort grows into a sustained campaign of close collaboration between FDA
and all patient communities, which continuously improves the system for
reviewing and approving innovative therapies.
Thank you.
